



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|   |           |   |
|---|-----------|---|
| <b>(51) International Patent Classification <sup>6</sup> :</b><br><b>C12N 15/10, C12Q 1/68</b>  | <b>A1</b> | <b>(11) International Publication Number:</b> <b>WO 98/41623</b><br><b>(43) International Publication Date:</b> 24 September 1998 (24.09.98)  |
| <b>(21) International Application Number:</b> PCT/DK98/00105<br><b>(22) International Filing Date:</b> 18 March 1998 (18.03.98)<br><br><b>(30) Priority Data:</b><br>0304/97 18 March 1997 (18.03.97) DK<br>0432/97 17 April 1997 (17.04.97) DK<br><br><b>(71) Applicant:</b> NOVO NORDISK A/S [DK/DK]; Novo Allé,<br>DK-2880 Bagsværd (DK).<br><br><b>(72) Inventors:</b> BORCHERT, Torben, Vedel; Smakkevej 1,<br>DK-4040 Jyllinge (DK). KRETZSCHMAR, Titus;<br>Kasperlmühlstrasse 6, D-81739 Munich (DE). CHERRY,<br>Joel, R.; 916 Anderson Road, Davis, CA 95616 (US).  |           | <b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR,<br>BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE,<br>GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ,<br>LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW,<br>MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,<br>TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent<br>(GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent<br>(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent<br>(AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,<br>MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,<br>GA, GN, ML, MR, NE, SN, TD, TG).<br><br><b>Published</b><br><i>With international search report.</i> |
| <b>(54) Title:</b> SHUFFLING OF HETEROLOGOUS DNA SEQUENCES<br><br><b>(57) Abstract</b><br><br>The present invention relates to a new method of shuffling especially heterologous polynucleotide sequences, screening and/or selection of new recombinant proteins resulting therefrom having a desired biological activity, and especially to production and identification of novel proteases exhibiting desired properties. The method comprises the following steps; i) identification of at least one conserved region between the heterologous sequences of interest; ii) generating fragments of each of the heterologous sequences of interest, wherein said fragments comprise the conserved region(s), in a preferred embodiment due to the use of parts of the regions(s) as primers; and iii) shuffling/recombining said fragments using the conserved region(s) as (a) homologous linking point(s). |           |   |

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |  |    |  |    |                          |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania                  | ES | Spain                                    | LS | Lesotho                                      | SI | Slovenia                 |
| AM | Armenia                  | FI | Finland                                  | LT | Lithuania                                    | SK | Slovakia                 |
| AT | Austria                  | FR | France                                   | LU | Luxembourg                                   | SN | Senegal                  |
| AU | Australia                | GA | Gabon                                    | LV | Latvia                                       | SZ | Swaziland                |
| AZ | Azerbaijan               | GB | United Kingdom                           | MC | Monaco                                       | TD | Chad                     |
| BA | Bosnia and Herzegovina   | GE | Georgia                                  | MD | Republic of Moldova                          | TG | Togo                     |
| BB | Barbados                 | GH | Ghana                                    | MG | Madagascar                                   | TJ | Tajikistan               |
| BE | Belgium                  | GN | Guinea                                   | MK | The former Yugoslav<br>Republic of Macedonia | TM | Turkmenistan             |
| BF | Burkina Faso             | GR | Greece                                   | ML | Mali   | TR | Turkey                   |
| BG | Bulgaria                 | HU | Hungary                                  | MN | Mongolia                                     | TT | Trinidad and Tobago      |
| BJ | Benin                    | IE | Ireland                                  | MR | Mauritania                                   | UA | Ukraine                  |
| BR | Brazil                   | IL | Israel                                   | MW | Malawi                                       | UG | Uganda                   |
| BY | Belarus                  | IS | Iceland                                  | MX | Mexico                                       | US | United States of America |
| CA | Canada                   | IT | Italy                                    | NE | Niger  | UZ | Uzbekistan               |
| CF | Central African Republic | JP | Japan                                    | NL | Netherlands                                  | VN | Viet Nam                 |
| CG | Congo                    | KE | Kenya                                    | NO | Norway                                       | YU | Yugoslavia               |
| CH | Switzerland              | KG | Kyrgyzstan                               | NZ | New Zealand                                  | ZW | Zimbabwe                 |
| CI | Côte d'Ivoire            | KP | Democratic People's<br>Republic of Korea | PL | Poland                                       |    |                          |
| CM | Cameroon                 | KR | Republic of Korea                        | PT | Portugal                                     |    |                          |
| CN | China                    | KZ | Kazakhstan                               | RO | Romania                                      |    |                          |
| CU | Cuba                     | LC | Saint Lucia                              | RU | Russian Federation                           |    |                          |
| CZ | Czech Republic           | LI | Liechtenstein                            | SD | Sudan  |    |                          |
| DE | Germany                  | LK | Sri Lanka                                | SE | Sweden                                       |    |                          |
| DK | Denmark                  | LR | Liberia                                  | SG | Singapore                                    |    |                          |
| EE | Estonia                  |    |  |    |  |    |                          |

TITLE: Shuffling of heterologous DNA sequences

FIELD OF THE INVENTION

The present invention relates to a new method of shuffling  
5 especially heterologous polynucleotide sequences, screening and/or  
selection of new recombinant proteins resulting therefrom having a  
desired biological activity, and especially to the production and  
identification of novel proteases exhibiting desired properties.

10 BACKGROUND OF THE INVENTION

It is generally found that a protein performing a certain  
bioactivity exhibits a certain variation between genera, and even  
between members of the same species differences may exist. This  
variation is even more outspoken at the genomic level.

15 This natural genetic diversity among genes coding for pro-  
teins having basically the same bioactivity has been generated in  
nature over billions of years and reflects a natural optimisation  
of the proteins coded for in respect of the environment of the or-  
ganism in question.

20 However, in general it has been found that the naturally oc-  
curring bioactive molecules are not optimized for the various uses  
to which they are put by mankind, especially when they are used  
for industrial purposes.

It has therefore been of interest to industry to identify  
25 such bioactive proteins that exhibit optimal properties in respect  
of the use for which it is intended.

This has been done for many years by screening of natural  
sources, or by use of mutagenesis. For instance, within the tech-  
nical field of enzymes for use in e.g. detergents, the washing  
30 and/or dishwashing performance of e.g. naturally occurring prote-  
ases, lipases, amylases and cellulases has been improved signifi-  
cantly by *in vitro* modifications of the enzymes.

In most cases these improvements have been obtained by site-  
directed mutagenesis resulting in substitution, deletion or inser-  
35 tion of specific amino acid residues which have been chosen either  
on the basis of their type or on the basis of their location in  
the secondary or tertiary structure of the mature enzyme (see for  
instance US patent no. 4,518,584).

Prior Art:

Numerous methods to create genetic diversity, such as by site directed or random mutagenesis, have been proposed and described in scientific literature as well as patent applications. For further details in this respect reference is made to the related art section of WO 95/22625, wherein a review is provided.

One method of the shuffling of homologous DNA sequences has been described by Stemmer (Stemmer, (1994), Proc. Natl. Acad. Sci. USA, Vol. 91, 10747-10751; Stemmer, (1994), Nature, vol. 370, 389-391). The method concerns shuffling homologous DNA sequences by using *in vitro* PCR techniques. Positive recombinant genes containing shuffled DNA sequences are selected from a DNA library based on the improved function of the expressed proteins.

WO 95/22625 is believed to be the most pertinent reference in relation to the present invention in its "gene shuffling" aspect. In WO 95/22625 a method for shuffling of homologous DNA sequences is described. An important step in the method described in WO 95/22625 is to cleave the homologous template double-stranded polynucleotide into random fragments of a desired size followed by homologously reassembling of the fragments into full-length genes.

A disadvantage inherent to the method of WO 95/22625 is, however, that the diversity generated through that method is limited due to the use of homologous gene sequences (as defined in WO 95/22625).

Another disadvantage in the method of WO 95/22625 lies in the production of the random fragments by the cleavage of the template double-stranded polynucleotide.

A further reference of interest is WO 95/17413 describing a method of gene or DNA shuffling by recombination of DNA sequences either by recombination of synthesized double-stranded fragments or recombination of PCR generated sequences. According to the method described in WO 95/17413 the recombination has to be performed among DNA sequences with sufficient sequence homology to enable hybridization of the different sequences to be recombined.

WO 95/17413 therefore also entails the disadvantage that the diversity generated is relatively limited.

The present invention does not contain any steps involving production of random fragments by the cleavage of the template double-stranded polynucleotide, as described in WO 95/22625.

Further, WO 95/22625 relates to shuffling of homologous  
5 genes, while the present invention relates to shuffling of heterologous genes.

#### SUMMARY OF THE INVENTION:

The problem to be solved by the present invention is to  
10 avoid the limitation of shuffling only homologous DNA sequences by providing a method to shuffle/recombine heterologous sequences of interest.

The solution is to use at least one "conserved sequence region", wherein there is a sufficient degree of homology between  
15 the heterologous sequences to be shuffled, as a "linking point" between said heterologous sequences.

Accordingly, a first aspect of the invention relates to a method of shuffling of heterologous sequences of interest comprising the following steps,

- 20 i) identification of at least one conserved region between the heterologous sequences of interest;
- ii) generating fragments of each of the heterologous sequences of interest, wherein said fragments comprise the conserved region(s); and
- 25 iii) shuffling/recombining said fragments using the conserved region(s) as (a) homologous linking point(s).

In an second aspect the invention relates to a method for producing a shuffled protein having a desired biological activity  
30 comprising in addition to the steps of the first aspect the further steps:

- iv) expressing the numerous different recombinant proteins encoded by the numerous different shuffled sequences from step iii); and
- 35 v) screen or select the numerous different recombinant proteins from step ii) in a suitable screening or selection system for one or more recombinant protein(s) having a desired activity.

The term "conserved region" denotes a sequence region (preferably of at least 10 bp), wherein there is a relatively high sequence identity between said heterologous sequences.

5 In order for the conserved region to be used as "linking point" between said heterologous sequences, the sequence identity between the heterologous sequences, within said conserved regions, is sufficiently high to enable hybridization of the heterologous sequences using said conserved region as hybridization point  
10 ("linking point").

#### BRIEF DESCRIPTION OF DRAWINGS

Fig. 1: Fig 1 illustrates the general concept of the invention,  
15 where

- a) the black boxes define mutual, common, conserved regions of the sequences of interest, and
- b) the PCR primers named "a,a',b,b',etc.." are primers directed to the conserved regions. Primers ("a'" and "b"), ("b'" and "c") etc.. have a sequence overlap of preferably at least 10  
20 bp, and
- c) primers "z" and "z'" are primers directed to the flanking parts of the sequence area of the sequences of interest which are shuffled according to the method of the invention.  
25

Fig 2: Shows an alignment of 5 protease (subtilase) DNA sequences. Herein are a number of conserved regions such as the common partial sequences numbered 1-5.

30 Fig 3: Shows an alignment of different lipases.

#### DEFINITIONS

Prior to discussing this invention in further detail, the following terms will be defined.

35 "Shuffling": The term "shuffling" means recombination of nucleotide sequence(s) between two or more DNA sequences of interest resulting in output DNA sequences (i.e. DNA sequences having been subjected to a shuffling cycle) having a number of nucleo-

tides exchanged, in comparison to the input DNA sequences (i.e. starting point DNA sequences of interest).

Alternatively, the term "shuffling" may be termed "recombining".

5 "Homology of DNA sequences": In the present context the degree of DNA sequence homology is determined as the degree of identity between two sequences indicating a derivation of the first sequence from the second. The homology may suitably be determined by means of computer programs known in the art, such as GAP provided in the GCG program package (Program Manual for the Wisconsin  
10 Package, Version 8, August 1994, Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA 53711)(Needleman, S.B. and Wunsch, C.D., (1970), Journal of Molecular Biology, 48, 443-453).

"Homologous": The term "homologous" means that one single-  
15 stranded nucleic acid sequence may hybridize to a complementary single-stranded nucleic acid sequence. The degree of hybridization may depend on a number of factors including the amount of identity between the sequences and the hybridization conditions such as temperature and salt concentration as discussed later  
20 (*vide infra*).

Using the computer program GAP (*vide supra*) with the following settings for DNA sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, it is in the present context believed that two DNA sequences will be able to hybridize (using  
25 medium stringency hybridization conditions as defined below) if they mutually exhibit a degree of identity of at least 50%, more preferably at least 60%, more preferably at least 70%, more preferably at least 80%, more preferably at least 85%, and even more preferably at least 90%.

30 "Heterologous": Two DNA sequences are said to be heterologous if one of them comprises a partial sequence of at least 40 bp which does not exhibit a degree of identity of more than 50%, more preferably of more than 70%, more preferably of more than 80%, more preferably of more than 85%, more preferably of more than  
35 90%, and even more preferably of more than 95%, of any partial sequence in the other. More preferably the first partial sequence is at least 60 bp, more preferably the first partial sequence is at least 80 bp, even more preferably the first partial sequence is at

least 120 bp, and most preferably the first partial sequence is at least 500 bp.

"Hybridization:" Suitable experimental conditions for determining if two or more DNA sequences of interest do hybridize or not are herein defined as hybridization at medium stringency as described in detail below.

A suitable experimental low stringency hybridization protocol between two DNA sequences of interest involves presoaking of a filter containing the DNA fragments to hybridize in 5 x SSC (Sodium chloride/Sodium citrate, Sambrook et al. 1989) for 10 min, and prehybridization of the filter in a solution of 5 x SSC, 5 x Denhardt's solution (Sambrook et al. 1989), 0.5 % SDS and 100 µg/ml of denatured sonicated salmon sperm DNA (Sambrook et al. 1989), followed by hybridization in the same solution containing a concentration of 10ng/ml of a random-primed (Feinberg, A. P. and Vogelstein, B. (1983) Anal. Biochem. 132:6-13), 32P-dCTP-labeled (specific activity > 1 x 10<sup>9</sup> cpm/µg ) probe (DNA sequence) for 12 hours at approx. 45°C. The filter is then washed twice for 30 minutes in 2 x SSC, 0.5 % SDS at least 55°C, more preferably at least 60°C, and even more preferably at least 65°C (high stringency).

Molecules to which the oligonucleotide probe hybridizes under these conditions are detected using an X-ray film.

"Alignment": The term "alignment" used herein in connection with an alignment of a number of DNA and/or amino acid sequences means that the sequences of interest are aligned in order to identify mutual/common sequences of homology/identity between the sequences of interest. This procedure is used to identify common "conserved regions" (*vide infra*), between sequences of interest. An alignment may suitably be determined by means of computer programs known in the art, such as PILEUP provided in the GCG program package (Program Manual for the Wisconsin Package, Version 8, August 1994, Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA 53711) (Needleman, S.B. and Wunsch, C.D., (1970), Journal of Molecular Biology, 48, 443-453).

"Conserved regions:" The term "conserved region" used herein in connection with a "conserved region" between DNA and/or amino acid sequences of interest means a mutual, common sequence region

of two or more sequences of interest, wherein there is a relatively high degree of sequence identity between two or more of the heterologous sequences of interest. In the present context a conserved region is preferably at least 10 base pairs (bp), more preferably at least 20 bp, and even more preferably at least 30 bp.

Using the computer program GAP (*vide supra*) with the following settings for DNA sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, the degree of DNA sequence identity within the conserved region, between two or more of the heterologous sequences of interest, is preferably at least 80%, more preferably at least 85%, more preferably at least 90%, and even more preferably at least 95%.

"Primer": The term "primer" used herein, especially in connection with a PCR reaction, is a primer (especially a "PCR-primer") defined and constructed according to general standard specification known in the art ("PCR A practical approach" IRL Press, (1991)).

"A primer directed to a sequence:" The term "a primer directed to a sequence" means that the primer (preferably to be used in a PCR reaction) is constructed so as to exhibit at least 80% degree of sequence identity to the sequence part of interest, more preferably at least 90% degree of sequence identity to the sequence part of interest, which said primer consequently is "directed to".

"Sequence overlap extension PCR reaction (SOE-PCR)": The term "SOE-PCR" is a standard PCR reaction protocol known in the art, and in the present context it is defined and performed according to standard protocols defined in the art ("PCR A practical approach" IRL Press, (1991)).

"Flanking": The term "flanking" used herein in connection with DNA sequences comprised in a PCR-fragment means the outmost end partial sequences of the PCR-fragment, both in the 5' and 3' ends of the PCR fragment.

"Subtilases": A serine protease is an enzyme which catalyzes the hydrolysis of peptide bonds, and in which there is an essential serine residue at the active site (White, Handler and Smith,

1973 "Principles of Biochemistry," Fifth Edition, McGraw-Hill Book Company, NY, pp. 271-272).

The bacterial serine proteases have molecular weights in the range of 20,000 to 45,000 Daltons. They are inhibited by diisopropylfluorophosphate. They hydrolyze simple terminal esters and are similar in activity to eukaryotic chymotrypsin, also a serine protease. A more narrow term, alkaline protease, covering a sub-group, reflects the high pH optimum of some of the serine proteases, from pH 9.0 to 11.0 (for review, see Priest (1977) Bacteriological Rev. 41 711-753).

A sub-group of the serine proteases tentatively designated subtilases has been proposed by Siezen et al., Protein Engng. 4 (1991) 719-737. They are defined by homology analysis of more than 40 amino acid sequences of serine proteases previously referred to as subtilisin-like proteases.

#### DETAILED DESCRIPTION OF THE INVENTION

##### A method for shuffling heterologous sequences of interest

In a preferred embodiment the fragments generated in step ii) of the first aspect of the invention is generated by use of PCR technology.

Accordingly, an aspect of the invention relates to a method of shuffling of heterologous DNA sequences of interest, according to the first aspect of the invention, comprising the following steps

- i) identification of one or more conserved region(s) (hereafter named "A,B,C" etc..) in two or more of the heterologous sequences;
- ii) construction of at least two sets of PCR primers (each set comprising a sense and an anti-sense primer) for one or more conserved region(s) identified in i) wherein
  - in one set the sense primer (named: "a"=sense primer) is directed to a sequence region 5' (sense strand) of said conserved region (e.g. conserved region "A"), and the anti-sense primer (named "a'"=anti-sense primer) is directed either to a sequence region 3' (sense strand) of said conserved region or directed to a

- sequence region at least partially within said conserved region,  
and in another set the sense primer (named: "b"=sense primer) is directed either to a sequence region 5' (sense strand) of said conserved region or directed to a sequence region at least partially within said conserved region and the anti-sense primer (named: "b'"=anti-sense primer) is directed to a sequence region 3' (sense strand) of said conserved region (e.g. conserved region "A"), and  
the two sequence regions defined by the regions between primer set "a" and "a'" and "b" and "b'" (both said regions is including the actual primer sequences) have a homologous sequence overlap of at least 10 base pairs (bp) within the conserved region;
- iii) for one or more identified conserved regions of interest in step i) two PCR amplification reactions are performed with the heterologous DNA sequences in step i) as template, and where
- one of the PCR reactions uses the 5' primer set identified in step ii) (e.g. named "a","a'") and the second PCR reaction uses the 3' primer set identified in step ii) (e.g. named "b","b'");
- iv) isolation of the PCR fragments generated as described in step iii) for one or more of the identified conserved region in step i);
- v) pooling of two or more isolated PCR fragments from step iv) and performing a Sequence overlap extension PCR reaction (SOE-PCR) using said isolated PCR fragments as templates; and
- vi) isolation of the PCR fragment obtained in step v), wherein said isolated PCR fragment comprises numerous different shuffled sequences containing a shuffled mixture of the PCR fragments isolated in step iv), wherein said shuffled sequences are
- characterized in that the partial DNA sequences, originating from the homologous sequence overlaps in step ii), have at least 80%

identity to one or more partial sequences in one or more of the original heterologous DNA sequences in step i).

A method of producing one or more recombinant protein(s) having a  
5 desired biological activity

In an second aspect the invention relates to a method of producing a shuffled protein having a desired biological activity comprising in addition to the steps i) to vi) immediately above the further steps:

- 10 vii) expressing the numerous different recombinant proteins encoded by the numerous different shuffled sequences in step vi); and
- viii) screen or select the numerous different recombinant proteins from step vii) in a suitable screening or selection system for one or more recombinant protein(s)
- 15 having a desired activity.

Heterologous DNA sequences

The method of the present invention may be used to shuffle  
20 basically all heterologous DNA sequences of interest.

Preferably, it is used to shuffle heterologous DNA sequences encoding an enzymatic activity, such as amylase, lipase, cutinase, cellulase, oxidase, phytase, and protease activity.

An further advantage of the present method is that it makes  
25 it possible to shuffle heterologous sequences encoding different activities, e.g. different enzymatic activities.

The method of the invention is in particular suitable to shuffle heterologous DNA sequences encoding a protease activity, in particular a subtilase activity.

30 A number of subtilase DNA sequences are published in the art. A number of those subtilase DNA sequences are in the present context heterologous DNA sequences, and it is generally believed that they are mutually too heterologous to be shuffled by the shuffling methods presently known in the art (WO 95/17413, WO  
35 95/22625). However the method according to the invention enables shuffling of such sequences. For further details reference is made to a working example herein (*vide infra*).

Further, the present invention is suitable to shuffle different lipase sequences. For further details reference is made to a working example herein (*vide infra*).

The heterologous DNA sequences used as templates may beforehand have been cloned into suitable vectors, such as a plasmid. Alternatively, a PCR-reaction may be performed directly on microorganisms known to comprise the DNA sequence of interest according to standard PCR protocols known in the art.

10 Identification of one or more conserved regions in heterologous sequences:

Identification of conserved regions may be done by an alignment of the heterologous sequences by standard computer programs (*vide supra*).

15 Alternatively, the method may be performed on completely new sequences, where the relevant "conserved regions" are chosen as conserved regions which are known in the art to be conserved regions for this particular class of proteins.

*E.g.*, the method may be used to shuffle completely unknown  
20 subtilase sequences, which are known to be very conserved in *e.g.* regions around the active site amino acids. PCR reaction may then be performed directly on new unknown strains with primers directed to those conserved regions.

25 PCR-primers

The PCR primers are constructed according to the standard descriptions in the art. Preferably, they are 10-75 base pairs (bp) long.

30 Homologous sequence overlap

In step ii) of claim 3 of the invention the two sequence regions defined by the regions between primer set "a" and "a'" and "b" and "b'" (both said regions including the actual primer sequences) have a homologous sequence overlap of at least 10 base  
35 pairs (bp) within the conserved region.

Said homologous sequence overlap is more preferably of at least 15 bp, more preferably of at least 20 bp, and even more preferably of at least 35 bp.

The homologous sequence overlaps in step ii) of claim 3 have at least 80% identity to one or more partial sequences in one or more of the original heterologous DNA sequences in step i) of said claim, more preferably the homologous sequence overlaps in step  
5 ii) have at least 90% identity to one or more partial sequences in one or more of the original heterologous DNA sequences in step i) of said claim, and even more preferably the homologous sequence overlaps in step ii) have at least 95% identity to one or more partial sequences in one or more of the original heterologous DNA  
10 sequences in step i) of said claim.

#### PCR-reactions

If not otherwise mentioned the PCR-reaction performed according to the invention is performed according to standard proto-  
15 cols known in the art.

The term "Isolation of PCR fragment" is intended to cover an aliquot containing the PCR fragment. However, the PCR fragment is preferably isolated to an extent which removes surplus of primers, nucleotides, etc.

20 Further, the fragment used for SOE-PCR in step v) of claim 3, may alternatively be generated by other processes than the PCR amplification process described in step iii) of said claim. Suitable fragments used for the SOE-PCR in step v), may e.g. be generated by cutting out suitable fragments by restriction enzyme di-  
25 gestion at appropriate sites (e.g. restriction sites situated on each site of a conserved region identified in step i). Such alternative processes for generating such suitable fragments for use in the SOE-PCR in step v) are considered within the scope of the invention.

30 In an embodiment of the invention the PCR DNA fragment(s) is(are) prepared under conditions resulting in a low, medium or high random mutagenesis frequency.

To obtain low mutagenesis frequency the DNA sequence(s) (comprising the DNA fragment(s)) may be prepared by a standard PCR  
35 amplification method (US 4,683,202 or Saiki et al., (1988), Science 239, 487 - 491).

A medium or high mutagenesis frequency may be obtained by performing the PCR amplification under conditions which increase

the misincorporation of nucleotides, for instance as described by Deshler, (1992), GATA 9(4), 103-106; Leung et al., (1989), Technique, Vol. 1, No. 1, 11-15.

#### 5 Final shuffled sequences

One of the advantages of the present invention is that the final "shuffled sequences" in step vi) of claim 3 of the present invention only comprise sequence information which is originally derived from the original heterologous sequences of interest in  
10 step i) of said claim. The present invention does not use artificially made "linker sequences" to recombine one or more of the heterologous sequences, which is a strategy known in the art to e.g. be able to shuffle different domains in proteins, wherein each domain is encoded by different heterologous sequences (WO  
15 95/17413).

Accordingly, the invention relates to a method characterized in that each of the shuffled sequences, the partial DNA sequences, originating from the homologous sequence overlaps in step ii), only contains sequence information which is originally derived  
20 from the original heterologous sequences in step i) (in the first to third aspect of the invention) (i.e. said "homologous sequence overlaps" in step ii) has at least 80% identity to one or more partial sequences in one or more of the original heterologous DNA sequences in step i).

25 More preferably, the "homologous sequence overlaps" in step ii) have at least 90% identity to one or more partial sequences in one or more of the original heterologous DNA sequences in step i); and even more preferably the "homologous sequence overlaps" in step ii) have at least 95% identity to one or more partial se-  
30 quences in one or more of the original heterologous DNA sequences in step i), and most preferably the "homologous sequence overlaps" in step ii) have 100% identity to one or more partial sequences in one or more of the original heterologous DNA sequences in step i).

#### 35 Expressing the recombinant protein from the shuffled sequences

Expression of the recombinant protein encoded by the shuffled sequence of the present invention may be performed by use of

standard expression vectors and corresponding expression systems known in the art.

Suitable screening or selection system

5 In its second aspect the present invention relates to a method for producing one or more recombinant protein(s) having a desired biological activity.

A suitable screening or selection system will depend on the desired biological activity.

10 A number of suitable screening or selection systems to screen or select for a desired biological activity are described in the art. Examples are:

Strauberg et al. (Biotechnology 13: 669-673 (1995), which describes a screening system to screen for subtilisin variants  
15 having a calcium-independent stability;

Bryan et al. (Proteins 1:326-334 (1986)), which describes a screening assay to screen for proteases having enhanced thermal stability; and

WO 97/04079 which describes a screening assay to screen for  
20 lipases having an improved wash performance in washing detergents.

A preferred embodiment of the invention comprises screening or selection of recombinant protein(s), wherein the desired biological activity is performance in dish-washing or laundry detergents. Examples of suitable dish-washing or laundry detergents are  
25 disclosed in WO 97/04079 and WO 95/30011.

The invention is described in further detail in the following examples which are not in any way intended to limit the scope of the invention.

30 **MATERIALS AND METHODS**

Strains

E. coli strain: DH10B (Life Technologies)

35 Bacillus subtilis strain: DN1885 amyE. A derivative of B,s 168RUB200 (J. Bacteriology 172:4315-4321 (1990))

### Plasmids

pKH400: pKH400 was constructed from pJS3 (E. coli - B. subtilis shuttle vector containing a synthetic gene encoding for subtilase 309 (described by Jacob Schiødt et al. in Protein and Peptide letters 3:39-44 (1996)), by introduction of two BamHI sites at positions 1841 and 3992.

### **Protease sequences used for shuffling**

GenBank entries A13050\_1, D26542, A22550, Swiss-Prot entry  
10 SUBT\_BACAM P00782, and PD498 (Patent Application No. WO 96/34963).

### **General molecular biology methods**

Unless otherwise mentioned the DNA manipulations and transformations were performed using standard methods of molecular  
15 biology (Sambrook et al. (1989) Molecular cloning: A laboratory manual, Cold Spring Harbor lab., Cold Spring Harbor, NY; Ausubel, F. M. et al. (eds.) "Current protocols in Molecular Biology". John Wiley and Sons, 1995; Harwood, C. R., and Cutting, S. M. (eds.) "Molecular Biological Methods for Bacillus". John Wiley and Sons,  
20 1990).

Enzymes for DNA manipulations were used according to the specifications of the suppliers.

### **Enzymes for DNA manipulations**

25 Unless otherwise mentioned all enzymes for DNA manipulations, such as e.g. restriction endonucleases, ligases etc., are obtained from New England Biolabs, Inc.

### **EXAMPLES**

30

#### **EXAMPLE 1**

##### **A) Vector construction**

##### **35 1) Amplification of the pre-pro sequences**

Host cells harboring the plasmid DNA encoding the full length enzymes A13050\_1 (GenBank), SUBT\_BACAM P00782 (Swiss-Prot), D26542 (GenBank), A22550 (GenBank), and PD498 (Patent Application No. WO

96/34963) were starting material. By standard mini-prep isolation of plasmid DNA, purified DNA was obtained. With these template DNAs, 5 standard PCRs were performed to amplify the respective pre-pro sequences. The fragments were generated using the proof reading Pwo DNA polymerase (Boehringer Mannheim) and the following sets of primers directed against the very N- and C-termini of the respective pre-pro sequences:

A13050\_1

10 TiK111: 5' GAG GAG GGA AAC CGA ATG AGG AAA AAG AGT TTT TGG.  
TiK117: 5' CGC GGT CGG GTA CCG TTT GCG CCA AGG CAT G.

SUBT\_BACAM P00782

TiK112: 5' GAG GAG GGA AAC CGA ATG AGA GGC AAA AAA GTA TGG.  
15 TiK118: 5' CGC GGT CGG GTA CCG ACT GCG CGT ACG CAT G.

D26542

TiK110: 5' GAG GAG GGA AAC CGA ATG AGA CAA AGT CTA AAA GTT ATG.  
TiK116: 5' CGC GGT CGG GTA CCG TTT GAC TGA TGG TTA CTT C.

20

A22550

TiK109: 5' GAG GAG GGA AAC CGA ATG AAG AAA CCG TTG GGG.  
TiK115: 5' CGC GGT CGG GTA CCG ATT GCG CCA TTG TCG TTA C.

25 PD498

TiK113: 5' GAG GAG GGA AAC CGA ATG AAG TTC AAA AAA ATA GCC.  
TiK119: 5' CGC GGT CGG GTA CCG CAG AAT AGT AAG GGT CAT TC.

The obtained DNA fragments of a length between 300-400 bp  
30 were purified by agarose gel-electrophoresis with subsequent gel extraction (QIAGEN) and subjected to assembly by splice-by-overlap extension PCR (SOE-PCR).

2) SOE-PCR

35 The pre-pro fragments were then separately spliced by SOE-PCR to the 3' part of the promoter of the vector pKH400. The 3' part of the promoter was obtained by standard PCR with the Pwo DNA polymerase using 1 ng of pKH400 as template and the primers:

TiK106: 5' CGA CGG CCA GCA TTG G.

TiK107: 5' CAT TCG GTT TCC CTC CTC.

The resulting 160 bp fragment was gel-purified. Subsequently, 5 SOE-PCRs were performed under standard conditions (Pwo DNA polymerase) using as template each of the 5 pre-pro sequences mixed with equal molar amounts of the 3' part of the promoter. The assembling primers were:

TiK120: 5' CTT TGA TAC GTT TAA ACT ACC.

TiK121: 5' CGC GGT CGG GTA CCG.

10 The obtained fragments were also gel-purified.

3) Insertion of the pre-pro sequences into the pKH400 shuttle vector

The pKH400 vector was cut with Pme I and Acc65 I to remove  
15 the existing linker sequence. The 5 purified SOE-PCR fragments from 2) were also digested with the same enzymes and gel-purified. Only with the SOE-PCR of the SUBT\_BACAM P00782 pre-pro sequence special caution was required because it contains an internal Pme I-site so that a partial digest was performed. In separate stan-  
20 dard ligation mixes the pre-pro fragments were then ligated to the pKH400 vector. After transformation of DH10B E.coli cells, colonies were selected on ampicillin containing media. Correctly transformed cells were identified by control digest and sequenced. The thus obtained vectors were named pTK4001-4005.

25

B) Preparation of the small fragments of the protéases A13050\_1 (GenBank), SUBT\_BACAM P00782 (Swiss-Prot), D26542 (GenBank), A22550 (GenBank), and PD498 (Patent Application No. WO 96/34963).

30 1) Standard PCR reactions were assembled with 0.5 µl of mini-prep DNA of each protease gene as templates. Since these five protease genes shall be fragmented into six fragments (I-VI), 30 PCRs are required (see fig 1). The Ampli-Taq polymerase (5U) was used in combination with the following primer sets (the numbering corre-  
35 sponds to the amino acid position in A22550). If there are primers labeled #.1, #.2, etc., then equal molar amounts of them are mixed prior to PCR and treated as one primer in the PCR:

## Set I)

TiK122.1 (116-124)

5' CCG GCG CAG GCG GTA CCX TRS GGX ATW XCX CXX RTX MAA GC.

TiK122.2 (116-124)

5 5' CCG GCG CAG GCG GTA CCX TRS GGX ATW XCA WWC ATX WAT AC.

TiK123 (174-180)

5' GTT CCX GCX ACR TGX GTX CC.

## Set II)

10 TiK124 (174-180)

5' GGX ACX CAY GTX GCX GGA AC.

TiK125.1 (217-223)

5' GCC CAC TSX AKX CCG YTX AC.

TiK125.2 (217-223)

15 5' GCC CAC TSX AKX CCT YGX GC.

TiK125.3 (217-223)

5' GCC CAX TSR AKX CCK XXX RCW AT.

## Set III)

20 TiK126.1 (217-223)

5' GTX ARC GGX MTX SAG TGG GC.

TiK126.2 (217-223)

5' GCX CRA GGX MTX SAG TGG GC.

TiK126.3 (217-223)

25 5' TWG CYC AAG GWW TXS AXT GKR.

TiK126.5 (217-223)

5' TWG CTC AAG GHH THS ART GG.

TiK127.1 (255-261)

5' GCX GCX ACX ACX ASX ACX CC.

30 TiK127.2 (255-261)

5' GCY SCW AYW AMX AGW AYA YCA.

## Set IV)

TiK128.1 (255-261)

35 5' GGX GTX STX GTX GTX GCX GC.

TiK128.2 (255-261)

5' TGR TRT WCT MKT WRT WGS RGC.

TiK129.1 (292-299)

5' GBX CCX ACR YTX GAR AAW GAX G.

TiK129.2 (292-299)

5' GBX CCR TAC TGX GAR AAR CTX G.

TiK129.3 (292-299)

5 5' GKX CCA TAC KKA GAR AAR YTT G.

TiK129.5 (292-299)

5' GKR CCA TAC KKA GAR AAG YTT G.

Set V)

10 TiK130.1 (292-299)

5' CXT CWT TYT CXA RYG TXG GXV C.

TiK130.2 (292-299)

5' CXA GYT TYT CXC AGT AYG GXV C.

TiK130.3 (292-299)

15 5' CAA GYT TCT CTM MGT ATG GSM C.

TiK130.5 (292-299)

5' CAA GTT TCT CTC AGT ATG GGA C.

TiK131.1 (324-330)

5' GGX GWX GCC ATX GAY GTX CC.

20 TiK131.2 (324-330)

5' GGA GTA GCC ATX GAX GTW CC.

Set VI)

TiK132.1 (324-330)

25 5' GGX ACR TCX ATG GCX WCX CC.

TiK132.2 (324-330)

5' GGW ACX TCX ATG GCA WCX CC.

TiK133.1 (375-380)

5' CGG CCC CGA CGC GTT TAC YGX RYX GCX SYX TSX RC.

30 TiK133.2 (375-380)

5' CGG CCC CGA CGC GTT TAT CKT RYX GCX XXY TYW G.

TiK133.3 (375-380)

5' CGG CCC CGA CGC GTT TAT CKT RCX GCX GCX TYT GMR TT.

TiK133.4 (375-380)

35 5' CGG CCC CGA CGC GTT TAT CTT ACG GCA GCC TCA GC.

(X = deoxy-inosine, Y = 50% C + 50% T, R = 50% A + 50% G, S = 50% C + 50% G, W = 50% A + 50% T, K = 50% T + 50% G, M = 50% A + 50%

C, B = 33.3% C + 33.3% G + 33.3% T, V = 33.3% C + 33.3% G + 33.3% A, H = 33.3% C + 33.3% A + 33.3%).

After 30 cycles at annealing temperatures ranging from 40-5 60°C the amplified fragments were gel-purified and recovered.

2) SOE-PCR to randomly assemble the small fragments

Equimolar amounts of each of the purified fragments were taken and mixed in one tube as templates for assembly in an other-10 wise standard SOE-PCR with Ampli-Taq polymerase. The external primers used are:

TiK134.1: CCG GCG CAG GCG GTA CC.

TiK135.1: CGG CCC CGA CGC GTT TA.

15 Also the primer pairs

TiK134.2: GGC GCA GGC GGT AC.

TiK135.2: GCC CCG ACG CGT TTA.

and

TiK134.3: CGC AGG CGG TAC.

20 TiK135.3: CCC GAC GCG TT.

can be used. The annealing temperatures are ranging from 40°C to 70°C.

The re-assembly is also achieved by sequentially re-assembling all conceivable combinations of fragments, e.g.: In25 tube 1 all seven fragments obtained by PCR with the primers of set I (see above, B1-2) are mixed, in tube 2 fragments obtained by PCR with the primers of set II are mixed, in tube 3 fragments obtained by PCR with the primers of set III are mixed, in tube 4 fragments obtained by PCR with the primers of set IV are mixed, in tube 530 fragments obtained by PCR with the primers of set V are mixed, in tube 6 fragments obtained by PCR with the primers of set VI are mixed.

Then, a SOE-PCR is performed by mixing aliquots of tube 1 and 2 and using the resulting mixture as template for a primary35 SOE-PCR with corresponding external primers. The same is performed with mixtures of aliquots of tubes 3 and 4 as well as tubes 5 and 6. The respective external primer pairs are TiK134.#/125.# for fragments 1 and 2, TiK126.#/129.# for fragments 3 and 4, and TiK

130.#/135.# for fragments 5 and 6. The amplified assembled fragments of about 340, 260, and 280 bp length, respectively, are purified by agarose gel electrophoresis. In a secondary SOE-PCR the obtained fragments are mixed and assembled using primer pair 5 TiK134.#/135.# as external primers. The obtained full-length protease genes are gel-purified as described above.

In another example, aliquots of tubes 1, 2, and 3 are mixed and re-assembled by a primary SOE-PCR with primer pair TiK134.#/127.#. Aliquots of tubes 4, 5, and 6 are also mixed in 10 another tube and re-assembled by another SOE-PCR using the primers TiK128.#/135.#. The generated fragments of about 450 bp length are purified as described above, mixed and reassembled in a secondary SOE-PCR with external primers TiK134.#/135.#. The obtained full-length protease genes are gel-purified as described above.

15 In principle, every combination of fragments may be assembled in separate SOE-PCRs. In subsequent SOE-PCRs the obtained assembled units are assembled to larger units until the final full length gene is obtained. The overall number of SOE-PCRs used for that purpose is only limited by experimental capacity. The only 20 prerequisite which is inherent to SOE-PCR is that the fragments to be assembled must contain a sequence overlap as defined earlier.

#### C) Cloning of the SOE-PCR-derived full-length protease-hybrids to yield library #1

25 The full-length protease-hybrid genes from step B2) as well as the newly constructed shuttle vectors pTK4001-4005 from A3) are separately digested with Acc65 I and Mlu I. In standard ligation procedures the protease genes are separately ligated to each of the five vectors pTK4001-4005 and transformed into E.coli DH10B. 30 Selection of correctly transformed cells is performed with ampicillin. DNA of these clones is prepared and designated library #1. The library size is about  $10^6$  independent transformants.

#### D) Screening of library #1

35 Aliquots of library #1 are used to transform Bacilli cells DN1885. The transformants are screened for the desired properties.

By this method and using a standard protease activity assay to screen for the desired property in step D) above a number of new shuffled subtilisins with a desired property were identified.

The results are indicated in Table 1 below.

5

Table 1

| Clone | pre-pro | frag.1<br>(5') | frag.2 | frag.3 | frag.4 | frag.5 | frag.6<br>(3') |
|-------|---------|----------------|--------|--------|--------|--------|----------------|
| 8     | BPN     | Sav            | Sav    | Sav    | Sav    | Sav    | Sav            |
| 6     | Alc     | Sav            | Sav    | Sav    | Sav    | Sav    | Sav            |
| 12    | Esp     | Sav            | Sav    | Sav    | Sav    | Sav    | Sav            |
| 10    | PD498   | Sav            | Sav    | Sav    | Sav    | Sav    | Sav            |
| 4     | Esp     | PD138          | Esp    | Esp    | Esp    | Esp    | JA16           |
| 22    | Alc     | PD138          | Esp    | Esp    | Esp    | Esp    | JA16           |
| 11    | PD498   | PD138          | Esp    | Esp    | Esp    | Esp    | JA16           |
| 1     | Alc     | PD138          | Esp    | PD138  | Esp    | Esp    | JA16           |
| 3     | BPN     | PD138          | Esp    | Esp    | PD138  | Sav    | Sav            |
| 17    | Esp     | PD138          | PD138  | Esp    | Esp    | Esp    | JA16           |
| 19    | PD498   | Alc            | BPN    | Esp    | Esp    | Esp    | JA16           |
| 16    | Alc     | Alc            | BPN    | Esp    | PD138  | Esp    | JA16           |

Identity of clones:

- 10 Alcalase: A13050\_1 (GenBank)    BPN': Poo782 (SwisProt)  
 Esperase: D26542 (GenBank)    Savinase: A22550 (GenBank)  
 PD498: WO 96/34963    JA16: WO 92/17576  
 PD138 WO 93/18140

15        23 clones having protease activity were identified of which 12 were different. Clones 8, 9, 18, 20, 23 were the same; clones 6, 15, 21 were the same, clones 12, 14 were the same, clones 10, 13 were the same, and clones 4, 7 were the same. In respect of mature enzymes 7 different were identified.

20        From Table 1 it is seen that the process of the invention makes it possible to obtain active proteins representing combinations of proteins quite distantly related.

## 25 Example 2

The same methods as described in example 1 can be used for amplification of PCR fragments from fungal lipases.

The fungal lipases from the following fungi are aligned using the alignment program from Geneworks (using the following pa-

rameters: cost to open a gap = 5, cost to lengthen a gap = 25, Minimum Diagonal lLength = 4, Maximum Diagonal Length = 10, Consensus cutoff = 50%): Rhizomucor Miehei (LIP\_RHIMI from the Swiss Prot data base), Rhizopus Delemar (LIP\_RHIDL from the Swiss Prot data base), Penecillium camenbertii (MDLA\_PENCA from the Swiss Prot data base) Absidia reflexa (WO 96/13578) and Humicola lanuginosa (US 5536661).

Primers for amplification of Absidia (Absidia), Rhizopus (LIP\_RHIDL) and Rhizomucor (LIP\_RHIMI) lipase genes for shuffling  
10 N: according to the IUPAC nomenclature means all 4 bases (A,T,G,C).

Set 1)

5' primer for YCRT/SVI/VPG: TAY TGY MGR ACN GTN ATH CCN GG or  
15 TAY TGY MGR AGY/TCN GTN GTN CCN GG  
3' primer for VFRGT/S: NSW NCC YCK RAA NAC

Set 2)

5' primer for VFRGT/S: GTN TTY MGR GGN WSN  
20 3' primer for KVHK/AGF: RAA NCC YTT RTG NAC YTT or  
RAA NCC NGC RTG NAC YTT

Set 3)

5' primer for KVHK/AGF: AAR GTN CAY AAR GGN TTY or  
25 AAR GTN CAY GCN GGN TTY  
3' primer for VTGHS LGG: CC NCC YAR NGA RTG NCC NGT NAC or  
CC NCC YAR RCT RTG NCC NGT NAC

Set 4)

30 5' primer for VTGHS LGG: GTN ACN GGN CAY TCN YTR GGN GG or  
GTN ACN GGN CAY AGY YTR GGN GG  
3' primer for FGFLH: RTG YAR RAA NCC RAA

Set 5)

35 5' primer for FGFLH: TTY GGN TTY YTR CAY  
3' primer for IVPFT: NGT RAA NGG NAC DAT

Primers for amplification of *Humicola lanuginosa* (*Humicola*) and *Penicillium camembertii* (MDLA\_PENCA) lipase genes for shuffling

Set 1)

- 5 5' primer for CPEVE: TGY CCN GAR GTN GAR  
3' primer for VLS/AFRG: NCC YCK RAA NGM YAR NAC

Set 2)

- 5' primer for VLS/AFRG: GTN YTR KCN TTY MGR GGN  
10 3' primer for GFT/WSSW: CCA NGA NGA NGT RAA NCC or  
CCA RSW RSW CCA RAA NCC

Set 3)

- 5' primer for GFT/WSSW: GGN TTY ACN TCN TCN TGG or  
15 GGN TTY TGG WSY WSY TGG  
3' primer for GHSLGG/AA: NGC NSC NCC YAR NGA RTG NCC or  
NGC NSC NCC YAR RCT RTG NCC

Set 4)

- 20 5' primer for GHSLGG/AA: GGN CAY TCN YTR GGN GSN GCN or  
GGN CAY AGY YTR GGN GSN GCN  
3' primer for PRVGN: RTT NCC NAC YCK NGG

Set 5)

- 25 5' primer for PRVGN: CCN MGR GTN GGN AAY  
3' primer for THTND: RTC RTT NGT RTG NGT

Set 6)

- 5' primer for THTND: ACN CAY ACN AAY GAY  
30 3' primer for PEYWI: DAT CCA RTA YTC NGG

Set 7)

- 5' primer for PEYWI: CCN GAR TAY TGG ATH  
35 3' primer for AHL/IWYF: RAA RTA CCA DAK RTG NGC

Primers for shuffling of all five genes:

## Set 1)

5' primer for AN/TA/SYCR: GCN AMY KCN TAY TGY MG for Absidia, Rhizopus and Rhizomucor sequences

5' primer for AN/TA/SYCGKNDA: GCN AMY KCN TAY TGY GGN AAR AAY AAY  
5 GAY GC for Humicola

5' primer for AN/TA/SYCEADYTA: GCN AMY KCN TAY TGY GAR GCN GAY TAY  
ACN GC for P. camenbertii

3' primer for E/QKTIY: RTA DAT NGT YTT YTS for Absidia, Rhizopus  
10 and Rhizomucor sequences

3' primer for ALDNTE/QKTIY: RTA DAT NGT YTT YTS NGT RTT RTC YAR  
NGC for Humicola

3' primer for AVDHTE/QKTIY: RTA DAT NGT YTT YTS NGT RTG RTC NAC  
NGC for P. camenbertii

15

## Set 2)

5' primer for E/QKTIY: SAR AAR ACN ATH TAY for Absidia, Rhizopus  
and Rhizomucor sequences

5' primer for E/QKTIYLA/SFRG: SAR AAR ACN ATH TAY YTR KCN TTY MGR  
20 GGN for the two other sequences

3' primer for KVHK/AGF: RAA NCC YTT RTG NAC YTT or RAA NCC NGC RTG  
NAC YTT for Absidia, Rhizopus and Rhizomucor sequences

3' primer for ICSGCKVHK/AGF: RAA NCC YTT RTG NAC YTT RCA NCC NGA  
25 RCA DAT or RAA NCC NGC RTG NAC YTT RCA NCC NGA RCA DAT for Humi-  
cola

3' primer for LCDGCKVHK/AGF: RAA NCC YTT RTG NAC YTT RCA NCC RTC  
RCA YAR or RAA NCC NGC RTG NAC YTT RCA NCC RTC RCA YAR for P. ca-  
menbertii

30

## Set 3)

5' primer for KVHK/AGF: AAR GTN CAY AAR GGN TTY or AAR GTN CAY GCN  
GGN TTY for Absidia, Rhizopus and Rhizomucor sequences

5' primer for KVHK/AGFTSSW: AAR GTN CAY AAR GGN TTY ACN TCN TCN  
35 TGG or AAR GTN CAY GCN GGN TTY ACN TCN TCN TGG for Humicola

5' primer for KVHK/AGFWSSW: AAR GTN CAY AAR GGN TTY TGG WSY WSY  
TGG or AAR GTN CAY GCN GGN TTY TGG WSY WSY TGG for P. camenbertii

3' primer for GHSLGG/AA: NGC NSC NCC YAR NGA RTG NCC or NGC NSC  
NCC YAR RCT RTG NCC for all five sequences

Set 4)

5 5' primer for GHSLGG/AA: GGN CAY TCN YTN GGN GSN GCN or GGN CAY  
AGY YTN GGN GSN GCN for all five sequences

3' primer for PRVGN/D: RTY NCC NAC YCK NGG for all the genes ex-  
cept Absidia

10 3' primer for TQGQPRVGN/D: RTY NCC NAC YCK NGG YTG NCC YTG NGT for  
Absidia

Set 5)

5' primer for PRVGN/D: CCN MGR GTN GGN RAY for all the genes ex-  
15 cept Absidia

5' primer for PRVGN/DPAFA: CCN MGR GTN GGN RAY CCN GCN TTY GCN for  
Absidia

3' primer for RDIVPH/R/K: YK NGG NAC DAT RTC YCK for Absidia,  
20 Rhizopus and Rhizomucor sequences

3' primer for I/FTHTRDIVPH/R/K: YK NGG NAC DAT RTC YCK NGT RTG NGT  
RAW for the two other sequences

Set 6)

25 5' primer for RDIVPH/R/K: MGR GAY ATH GTN CCN MR for Absidia,  
Rhizopus and Rhizomucor sequences

5' primer for RDIVPH/R/KLP: MGR GAY ATH GTN CCN MRN YTR CCN for  
the two other sequences

30 3' primer for EYWIK/T: YKT DAT CCA RTA YTC for Rhizomucor, Humi-  
cola and P.camenbertii

3' primer for PGVEYWIK/T: YKT DAT CCA RTA YTC NAC NCC NGG for  
Rhizopus

3' primer for AGEEYWIK/T: YKT DAT CCA RTA YTC YTC NCC NGC for Ab-  
35 sidia

Set 7)

5' primer for EYWIK/T: GAR TAY TGG ATH AAR or GAR TAY TGG ATH ACN  
for Rhizomucor, Humicola and P.camenbertii

5' primer for EYWIKSGT: GAR TAY TGG ATH AAR WSY GGN ACN for  
5 Rhizopus

5' primer for EYWIKKDSS: GAR TAY TGG ATH AAR AAR GAY WSY WSY for  
Absidia

3' primer for DHLSY: RTA NGA/RCT YAR RTG RTC for Absidia, Rhizopus  
10 and Rhizomucor sequences

3' primer for IPDIPDHLSY: RTA NGA/RCT YAR RTG RTC NGG DAT RTC NGG  
DAT for Humicola

3' primer for TDFEDHLSY: RTA NGA/RCT YAR RTG RTC YTC RAA RTC NGT  
for P.camenbertii

15

For the SOE-PCR the 5' primers from the first set of primers  
and the 3' primer for the last set of primers can be used.

The SOE-PCR fragments can then be combined with a lipase 5'  
and 3' end, when the 5' and 3' ends have been generated by PCR.

20 The 5' end can be generated by PCR by using specific 5' primers  
(containing a sequence for the BamHI recognition site in the 5'  
end) for the 5' end of the genes of interest and using the comple-  
mentary sequence from the 5' primer from the first set of primers  
as the 3' primer. The 3' end can be generated by PCR by using spe-  
25 cific 3' primers (containing a sequence for the XbaI recognition  
site in the 5' end) for the 3' end of the genes of interest and  
the complementary sequence from the 3' primer from the last set of  
primers as the 5' primer.

A second SOE is then used to generate the complete sequence,  
30 by using the specific 5' and 3' primers from the genes of inter-  
est.

The genes can then be cloned into the yeast vector pJS026 as  
a BamHI-XbaI fragment (see WO 97/07205).

### Example 3

The overall same method as described in example 2 can be  
used for amplification and recombination of PCR fragments of  
Pseudomonas lipases. The term "overall same method" denotes that

it may be advantageous to use slightly different vectors as compared to example 2. Based on the sequence and primer information disclosed below it is a matter of routine for a person skilled in the art to modify the vectors etc. from example 2, in order to recombine below mentioned *Pseudomonas* lipases according to a shuffling method of the invention.

The *Pseudomonas* lipases mentioned below are aligned using the alignment program from Geneworks (using the following parameters: cost to open a gap = 5, cost to lengthen a gap = 25, Minimum Diagonal lLength = 4, Maximum Diagonal Length = 10, Consensus cutoff = 50%).

#### Pseudomonas lipases

*Pseudomonas aeruginosa* TE3285 (file ate3285d)

*Pseudomonas pseudoalcaligenes* M1 (Lipomax wt) (file pseudm1d)

*Pseudomonas* sp. SD705 (mature)(file spsd705d)

*Pseudomonas wisconsinensis* (file wisconsd) *Proteus vulgaris* K80 (file provulgd) *Pseudomonas fragi* IFO 12049 (file fr12049d).

Suitable primers for shuffling of *Pseudomonas* lipases:

I = Inosin, Numbers refer to the numbers in the alignment(see figure 4), S means sense strand, the antisense oligonucleotide is of course also used:

- 5 109-131  
S1: 5'-TA(C/T)CCIAT(C/T) (G/T) I(C/T)T(G/A) (G/A) (C/T) ICA(C/T)GG-3'
- 250-269  
S2: 5'-GA(G/A) (G/C) IICGIGGIG(A/C) I(G/C)A(G/A) (T/C)T-3'
- 10 318-343  
S3: 5'-GT(C/A)AA(C/T) (C/T)T(G/A)ITCGG(C/T)CA(C/T)AG(C/T)CAIGG-3'
- 607-628  
15 S4: 5'-  
TIAA(C/T) (G/C/A) (G/C/A) (C/T/A) (A/C) (A/G) I(T/C) (A/T) (C/T)CCI(C/T) (A/G) (T/G/A)GG-3'
- 801-817  
20 S5: 5'-AA(C/T)GA(C/T)GG(C/T) (C/A/T)TGGT(C/T/G)GG-3'
- 871-890  
S6: 5'-  
CA(C/T) (C/G)T(C/G)GA(C/T) (G/A) (A/C/T) (G/C) (G/A)T(G/C/A)AACCA-3'

## CLAIMS

1. A method for shuffling of heterologous sequences of interest comprising the following steps,
  - 5        i)        identification of at least one conserved region between the heterologous sequences of interest;
  - ii)        generating fragments of each of the heterologous sequences of interest, wherein said fragments comprise the conserved region(s); and
  - 10        iii)        shuffling/recombining said fragments using the conserved region(s) as (a) homologous linking point(s).
  
2. A method for producing a shuffled protein having a desired biological activity comprising in addition to the steps of the claim 15 1 the following further steps:
  - iv)        expressing the numerous different recombinant proteins encoded by the numerous different shuffled sequences from step iii) (in claim 1); and
  - v)        screen or select the numerous different recombinant  
20        proteins from step ii) in a suitable screening or selection system for one or more recombinant protein(s) having a desired activity.
  
3.        The method for shuffling of heterologous DNA sequences of  
25 interest, according to claim 1, having at least one conserved region comprising the following steps
  - i)        identification of one or more conserved region(s) (hereafter named "A,B,C" etc..) in two or more of the heterologous sequences;
  - 30        ii)        construction of at least two sets of PCR primers (each set comprising a sense and an anti-sense primer) for one or more conserved region(s) identified in i) wherein  
                in one set the sense primer (named: "a"=sense primer) is directed to a sequence region 5' (sense strand) of said  
35        conserved region (e.g. conserved region "A"), and the anti-sense primer (named "a'"=anti-sense primer) is directed  
                either to a sequence region 3' (sense strand) of said

- conserved region or directed to a sequence region at least partially within said conserved region,  
and in the second set the sense primer (named: "b"=sense primer) is directed either to a sequence region 5' (sense strand) of said conserved region or directed to a sequence region at least partially within said conserved region and the anti-sense primer (named: "b'"=anti-sense primer) is directed to a sequence region 3' (sense strand) of said conserved region (e.g. conserved region "A"), and  
the two sequence regions defined by the regions between primer set "a" and "a'" and "b" and "b'" (both said regions including the actual primer sequences) have a homologous sequence overlap of at least 10 base pairs (bp) within the conserved region;
- iii) for one or more identified conserved region of interest in step i) two PCR amplification reactions are performed with the heterologous DNA sequences in step i) as template, and where  
one of the PCR reactions is using the 5' primer set identified in step ii) (e.g. named "a","a'") and the second PCR reaction is using the 3' primer set identified in step ii) (e.g. named "b","b'");
- iv) isolation of the PCR fragments generated as described in step iii) for one or more of the identified conserved region in step i);
- v) pooling of two or more isolated PCR fragments from step iv) and performance of a Sequence overlap extension PCR reaction (SOE-PCR) using said isolated PCR fragments as templates; and
- vi) isolation of the PCR fragment obtained in step v), wherein said isolated PCR fragment comprises numerous different shuffled sequences containing a shuffled mixture of the PCR fragments isolated in step iv), wherein said shuffled sequences are  
characterized in that the partial DNA sequences, originating from the homologous sequence overlaps in step ii), have at least 80% identity to one or more partial sequences in one or more of the original heterologous DNA sequences in step i).

4. The method for producing one or more recombinant protein(s) having a desired biological activity, according to claim 2, comprising:
- 5 shuffling of heterologous DNA sequences, having at least one conserved region, encoding a protein by
- i) identification of one or more conserved region(s) (hereafter named "A,B,C" etc..) in two or more of the heterologous sequences;
- 10 ii) construction of at least two sets of PCR primers (each set comprising a sense and an anti-sense primer) for one or more conserved region(s) identified in i) wherein
- 15 in one set the sense primer (named: "a"=sense primer) is directed to a sequence region 5' (sense strand) of said conserved region (e.g. conserved region "A"), and the anti-sense primer (named "a'"=anti-sense primer) is directed either to a sequence region 3' (sense strand) of said conserved region or directed to a sequence region at least partially within said conserved region,
- 20 and in the second set the sense primer (named: "b"=sense primer) is directed either to a sequence region 5' (sense strand) of said conserved region or directed to a sequence region at least partially within said conserved region and the anti-sense primer (named: "b'"=anti-sense primer) is
- 25 directed to a sequence region 3' (sense strand) of said conserved region (e.g. conserved region "A"), and the two sequence regions defined by the regions between primer set "a" and "a'" and "b" and "b'" (both said regions is including the actual primer sequences) have a homologous sequence overlap of at least 10 base pairs (bp) within the
- 30 conserved region;
- iii) for one or more identified conserved region of interest in step i) two PCR amplification reactions are performed with the heterologous DNA sequences in step i) as template, and
- 35 where
- one of the PCR reactions is using the 5' primer set identified in step ii) (e.g. named "a","a'") and the second

- PCR reaction is using the 3' primer set identified in step ii) (e.g. named "b", "b'");
- iv) isolation of the PCR fragments generated as described in step iii) for one or more of the identified conserved region in step i);
- 5 v) pooling of two or more isolated PCR fragments from step iv) and performance of a Sequence overlap extension PCR reaction (SOE-PCR) using said isolated PCR fragments as templates; and
- 10 vi) isolation of the PCR fragment obtained in step v), wherein said isolated PCR fragment comprises numerous different shuffled sequences containing a shuffled mixture of the PCR fragments isolated in step iv), wherein said shuffled sequences are
- 15 characterized in that the partial DNA sequences, originating from the homologous sequence overlaps in step ii), have at least 80% identity to one or more partial sequences in one or more of the original heterologous DNA sequences in step i);
- 20 vii) expressing the numerous different recombinant proteins encoded by the numerous different shuffled sequences in step vi); and
- viii) screen or select the numerous different recombinant proteins from step vii) in a suitable screening or selection system
- 25 for one or more recombinant protein(s) having a desired activity.
5. The method according to any of claims 1-4, wherein the heterologous sequences of interest are encoding an enzyme.
- 30 6. The method according to claim 5, wherein the enzyme is a protease, preferably a serine protease, and in particular a subtilase; or a lipase.
- 35 7. The method according to any of claims 3 and 4, wherein the PCR amplification process in step iii) is performed under conditions resulting in a low, medium or high random mutagenesis frequency.

8. The method according to any of claims 2 and 4, wherein the desired activity is an activity which leads to performance of the recombinant protein(s) in a dish-wash or laundry detergent.

1/8




Fig. 1

2/8

1 M M R - K K S F W L G M L T A F M L V F T M A F S D S A S A A13050\_1.PRO  
 1 M - K - K P L G K I V A S T A L L I S - - V A F S S S I A S A22550.PRO  
 1 M - R - Q S L K V M V L S T - - - V A - - L L F M A N P A A D26542.PRO  
 1 M - R - G K K V W I S L L F A L A L I F T M A F G S T S S A P00782.PRO  
 1 M - K F K K I A A L S L A T S L A L F - - P A F G G S S L A PD498.PRO

30 A Q P - - - - - A K - N V E K - - - - - D - Y I V G F A13050\_1.PRO  
 27 A A E - - - - - E A - - - - - K - - - - - E K Y L I - - A22550.PRO  
 24 A S E - - - - - E K - - - - - K - - - - - E - Y L I - - D26542.PRO  
 29 Q A A - - - - - G K S N G E K - - - - - K - Y I V G F P00782.PRO  
 28 K E A P K P F Q P I N K - T L D K G A F E S G E - V I V K E PD498.PRO

45 K S G - - - - - - - - - - - V K - - T - - A S V K K D A13050\_1.PRO  
 38 - - - G F N E Q E A V S E F V E Q V E - - A N D E V A I L S A22550.PRO  
 34 - - - - - - - - - - - V V - - E P E E V S A Q S D26542.PRO  
 45 K Q T - - - - - - - - - - - M S - - T M S A A K K K D P00782.PRO  
 56 K D G - - - - - - - - - - - V S K K A Q G S A L N K A PD498.PRO

57 I I K E S G G K V O K Q F R I I N A A K A K L D K E A L K E A13050\_1.PRO  
 63 E E E E V E I E L L H E F E T I P V L S V E L S P E D V D A A22550.PRO  
 45 V E E S Y D V D V I H E F E E I P V I H A E L T K K E L K K D26542.PRO  
 59 V I S E K G G K V Q K Q F K Y V D A A S A T L N E K A V K E P00782.PRO  
 72 E A N E Q K A S A K D P E Q V L E V A D V - - - D Q A V K A PD498.PRO

87 V K N D P D V A Y V E E D - - - - - - H V A H A L A Q T V A13050\_1.PRO  
 93 L E L D P A I S Y I E E D - - - - - - A E V T T M A Q S V A22550.PRO  
 75 L K K D P N V K A I E E N - - - - - - A E V T - I S Q T V D26542.PRO  
 89 L K K D P S V A Y V E E D - - - - - - H V A H A Y A Q S V P00782.PRO  
 99 L E N N P N V E Y A E P N Y T F Q A T W S P N D P Y Y S A Y PD498.PRO

110 P Y G I P L I K A D K V Q A Q G F K G A N V K V A V L D T G A13050\_1.PRO  
 116 P W G I S R V Q A P A A H N R G L T G S G V K V A V L D T G A22550.PRO  
 97 P W G I S F I N T Q Q A H N R G I F G N G A R V A V L D T G D26542.PRO  
 112 P Y G V S Q I K A P A L H S Q G Y T G S N V K V A V I D S G P00782.PRO  
 129 Q Y G P Q N T S T P A A W D V T R G S S T Q T V A V L D S G PD498.PRO

140 I Q A S H P D L - - N V V G G A S F V A G E A Y N - T D G N A13050\_1.PRO  
 146 I - S T H P D L - - N I R G G A S F V P G E P S T - Q D G N A22550.PRO  
 127 I - A S H P D L - - R I A G G A S F I S S E P S Y - H D N N D26542.PRO  
 142 I D S S H P D L - - K V A G G A S M V P S E T N P F Q D N N P00782.PRO  
 159 V D Y N H P D L A R K V I K G Y D E I D R D N N P - M D L N PD498.PRO

167 G H G T H V A G T V A A - L D N T T G V L G V A P S V S L Y A13050\_1.PRO  
 172 G H G T H V A G T I A A - L N N S I G V L G V A P S A E L Y A22550.PRO  
 153 G H G T H V A G T I A A - L N N S I G V L G V A P S A D L Y D26542.PRO  
 170 S H G T H V A G T V A A - L N N S I G V L G V A P S A S L Y P00782.PRO  
 188 G H G T H V A G T V A A D T N N G I G V A G M A P D T K I L PD498.PRO

196 A V K V L N S S G S G S Y S G I V S G I E W A T T N G M D V A13050\_1.PRO  
 201 A V K V L G A S G S G S V S S I A Q G L E W A G N N G M H V A22550.PRO  
 182 A V K V L D R N G S G S L A S V A Q G I E W A I N N N M H I D26542.PRO  
 199 A V K V L G A D G S G Q Y S W I I N G I E W A I A N N M D V P00782.PRO  
 218 A V R V L D A N G S G S L D S I A S G I R Y A A D Q G A K V PD498.PRO

Fig. 2 (a)  
 SUBSTITUTE SHEET (RULE 26)

3/8

|     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |              |              |
|-----|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|--------------|--------------|
| 226 | I | N | M | S | L | G | G | A | S | G | S | T | A | M | K | Q | A | V | D | N | A | Y | A | R | G | V | V | V | V | A            | A13050_1.PRO |
| 231 | A | N | L | S | L | G | S | P | S | P | S | A | T | L | E | Q | A | V | N | S | A | T | S | R | G | V | L | V | V | A            | A22550.PRO   |
| 212 | I | N | M | S | L | G | S | T | S | G | S | S | T | L | E | L | A | V | N | R | A | N | N | A | G | I | L | L | V | G            | D26542.PRO   |
| 229 | I | N | M | S | L | G | G | P | S | G | S | A | A | L | K | A | A | V | D | K | A | V | A | S | G | V | V | V | V | A            | P00782.PRO   |
| 248 | L | N | L | S | L | G | C | E | C | N | S | T | T | L | K | S | A | V | D | Y | A | W | N | K | G | A | V | V | V | A            | PD498.PRO    |
| 256 | A | A | G | N | S | G | S | S | G | N | T | N | T | I | G | Y | P | A | K | Y | D | S | V | I | A | V | G | A | V | D            | A13050_1.PRO |
| 261 | A | S | G | N | S | G | A | G | S | I | S | - | - | - | - | Y | P | A | R | Y | A | N | A | M | A | V | G | A | T | D            | A22550.PRO   |
| 242 | A | A | G | N | T | G | R | Q | G | V | N | - | - | - | - | Y | P | A | R | Y | S | G | V | M | A | V | A | A | V | D            | D26542.PRO   |
| 259 | A | A | G | N | E | G | T | S | G | S | S | S | T | V | G | Y | P | G | K | Y | P | S | V | I | A | V | G | A | V | D            | P00782.PRO   |
| 278 | A | A | G | N | D | N | V | S | R | T | F | - | - | - | - | Q | P | A | S | Y | P | N | A | I | A | V | G | A | I | D            | PD498.PRO    |
| 286 | S | N | S | N | R | A | S | F | S | S | V | G | A | E | L | E | V | M | A | P | G | A | G | V | Y | S | T | Y | P | T            | A13050_1.PRO |
| 287 | Q | N | N | N | R | A | S | F | S | Q | Y | G | A | G | L | D | I | V | A | P | G | V | N | V | Q | S | T | Y | P | G            | A22550.PRO   |
| 268 | Q | N | G | Q | R | A | S | F | S | T | Y | G | P | E | I | E | I | S | A | P | G | V | N | V | N | S | T | Y | T | G            | D26542.PRO   |
| 289 | S | S | N | Q | R | A | S | F | S | S | V | G | P | E | L | D | V | M | A | P | G | V | S | I | Q | S | T | L | P | G            | P00782.PRO   |
| 304 | S | N | D | R | K | A | S | F | S | N | Y | G | T | W | V | D | V | T | A | P | G | V | N | I | A | S | T | V | P | N            | PD498.PRO    |
| 316 | N | T | Y | A | T | L | N | G | T | S | M | A | S | P | H | V | A | G | A | A | A | L | I | L | S | K | H | P | N | L            | A13050_1.PRO |
| 317 | S | T | Y | A | S | L | N | G | T | S | M | A | T | P | H | V | A | G | A | A | A | L | V | K | Q | K | N | P | S | W            | A22550.PRO   |
| 298 | N | R | Y | V | S | L | S | G | T | S | M | A | T | P | H | V | A | G | V | A | A | L | V | K | S | R | Y | P | S | Y            | D26542.PRO   |
| 319 | N | K | Y | G | A | Y | N | G | T | S | M | A | S | P | H | V | A | G | A | A | A | L | I | L | S | K | H | P | N | W            | P00782.PRO   |
| 334 | N | G | Y | S | Y | M | S | G | T | S | M | A | S | P | H | V | A | G | L | A | A | L | L | A | S | Q | - | - | G | K            | PD498.PRO    |
| 346 | S | A | S | Q | V | R | N | R | L | S | S | T | A | T | Y | L | - | - | - | G | S | S | F | Y | Y | G | K | G | L | I            | A13050_1.PRO |
| 347 | S | N | V | Q | I | R | N | H | L | K | N | T | A | T | S | L | - | - | - | G | S | T | N | L | Y | G | S | G | L | V            | A22550.PRO   |
| 328 | T | N | N | Q | I | R | Q | R | I | N | Q | T | A | T | Y | L | - | - | - | G | S | P | S | L | Y | G | N | G | L | V            | D26542.PRO   |
| 349 | T | N | T | Q | V | R | S | S | L | E | N | T | T | T | K | L | - | - | - | G | D | S | F | Y | Y | G | K | G | L | I            | P00782.PRO   |
| 362 | N | N | V | Q | I | R | Q | A | I | E | Q | T | A | D | K | I | S | G | T | G | T | N | F | K | Y | G | K | - | - | I            | PD498.PRO    |
| 373 | N | V | E | A | A | A | Q |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   | A13050_1.PRO |              |
| 374 | N | A | E | A | A | T | R |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   | A22550.PRO   |              |
| 355 | H | A | G | R | A | T | Q |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   | D26542.PRO   |              |
| 376 | N | V | Q | A | A | A | Q |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   | P00782.PRO   |              |
| 390 | N | S | N | K | A | V | R | Y |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   | PD498.PRO    |              |

Fig. 2 (b)

SUBSTITUTE SHEET (RULE 26)

Percent Similarity

|   | 1     | 2     | 3     | 4    | 5    |   |
|---|-------|-------|-------|------|------|---|
| 1 |       | 52.2  | 48.6  | 66.5 | 41.8 | 1 |
| 2 | 74.2  |       | 59.9  | 51.6 | 41.8 | 2 |
| 3 | 83.6  | 56.7  |       | 48.1 | 39.4 | 3 |
| 4 | 44.2  | 75.6  | 85.2  |      | 45.4 | 4 |
| 5 | 100.0 | 100.0 | 100.0 | 93.1 |      | 5 |
|   | 1     | 2     | 3     | 4    | 5    |   |

A13050\_1.PRO

A22550.PRO

D26542.PRO

P00782.PRO

PD498.PRO

Fig. 2 (c)

SUBSTITUTE SHEET (RULE 26)

5/8

|            |            |            |            |            |            |     |
|------------|------------|------------|------------|------------|------------|-----|
| LIP_RHIMI  | MV-LKQRANY | LGF-LIVFFT | AFLVEAVPI- | -KRQSNSTV- | -----DSLPP | 40  |
| LIP_RHIDL  | MVSFISISQG | VSLCLLVSSM | MLGSSAVPVS | GKSGSSNTAV | SASDNAALPP | 50  |
| ABSIDIA    | M-----HSHF | VVLLLAVFIC | MCSVSGVPL- | -QIDPRDDK- | -----SYVPE | 37  |
| MDLA_PENCA | M-----R    | LSFFTALSA- | ---VASLG-- | -----      | ---YA-LPG  | 21  |
| Humicola   | M-----R    | SSL--VLFF- | ---VSAWT-- | -----      | -----A-LAS | 18  |
| Consensus  | M-----.... | .SL.L.VF.. | ...VSAVP.- | -----      | -----A.LP. | 50  |
| .          |            |            |            |            |            |     |
| LIP_RHIMI  | LIPSRTSAPS | SSPSTTDPEA | -P-AM----- | ---SRNGPLP | S--DVETKY- | 77  |
| LIP_RHIDL  | LISSRCAPPS | NKGSKSDLQA | EPYNMQKNT  | WYESHGGNLT | SIGKRDDNLV | 100 |
| ABSIDIA    | QYPLKVNGPL | PEGVSVIQGY | -----      | ---CENCTMY | P----EKN-- | 68  |
| MDLA_PENCA | KLQSR----- | -----      | -----      | -----      | -----D---- | 27  |
| Humicola   | PIR-R----- | -----      | -----      | -----      | -----E---- | 23  |
| Consensus  | .I.SR...P. | .....      | -----      | -----      | -----E---- | 100 |
| .          |            |            |            |            |            |     |
| LIP_RHIMI  | -GMALNATSY | PDSVVQAMSI | ----DGG-IR | AATSQEINEL | TYTTLSANS  | 121 |
| LIP_RHIDL  | GGMTLDLPSP | APPISLSSST | NSASDGGKV  | AATTAQIQEF | TKYAGIAATA | 150 |
| ABSIDIA    | -----SVSAF | SSSSTQDYRI | -----      | -ASEAEIKAH | TFYTALSANA | 102 |
| MDLA_PENCA | -----      | -----      | -----      | -VSTSELDQF | EFWVQYAAAS | 46  |
| Humicola   | -----      | -----      | -----      | -VSQDLFNQF | NLFAQYSAAA | 42  |
| Consensus  | -----..... | .....      | -----      | -AS..EI..F | T.Y...SA.A | 150 |
| .          |            |            |            |            |            |     |
| LIP_RHIMI  | YC---RTVIP | GATWDCI--H | C-DA-TEDLK | IIKTWS-TLI | YDTNAMVARG | 163 |
| LIP_RHIDL  | YC---RSVVP | GNKWDCV--Q | C-QKWVPDQK | IITFT-SLL  | SDTNGYVLRS | 193 |
| ABSIDIA    | YC---RTVIP | GGRWSCP--H | C-GV-ASNLQ | ITKTFS-TLI | TDTNVLVAVG | 144 |
| MDLA_PENCA | YYEADYTAQV | GDKLSCSKGN | CPEVEATGAT | VSYDFSSTI  | TDTAGYIAVD | 96  |
| Humicola   | YCGKNNDAPA | GTNITCTGNA | CPEVEKADAT | FLYSFEDSGV | GDVTGFLALD | 92  |
| Consensus  | YC---RTV.P | G..W.C.--  | C-.V...D.. | I..TFS-SLI | .DTNG.VA.. | 200 |
| .          |            |            |            |            |            |     |
| LIP_RHIMI  | DSEKTIYIVF | RGSSSIRNWI | ADLTFVPVSY | PPV-SGTKVH | KGFLDSYGEV | 212 |
| LIP_RHIDL  | DKQKTIYLVF | RGTNSFRSAI | TDIVFNFSY  | KPV-KGAKVH | AGFLSSYEQV | 242 |
| ABSIDIA    | EKEKTIYVVF | RGTSSIRNAI | ADIVFVPVNY | PPV-NGAKVH | KGFLDSYNEV | 193 |
| MDLA_PENCA | HTNSAVVLAF | RGSYSVRNVV | ADATF-VHTN | PGLCDGCLAE | LGFWSWKLV  | 145 |
| Humicola   | NTNKLIVLSF | RGSRSIENWI | GNLNFDLKEI | NDICSGCRGH | DGFTSSWRSV | 142 |
| Consensus  | ...KTIYLVF | RGS.SIRNWI | AD..F....Y | PPV-.G.KVH | .GFLSSY..V | 250 |
| .          |            |            |            |            |            |     |
| LIP_RHIMI  | QNELVATVLD | QFKQYPSYKV | AVTGHSLGGA | TALLCALDLY | QREEGLSSSN | 262 |
| LIP_RHIDL  | VNDYFPVVQE | QLTAHPTYKV | IVTGHSLGGA | QALLAGMDLY | QREPLSPKN  | 292 |
| ABSIDIA    | QDKLVAEVKA | QLDRHPGYKI | VVTGHSLGGA | TAVLSALDLY | HHGH----AN | 239 |
| MDLA_PENCA | RDDIIKELKE | VVAQNPNYEL | VVTGHSLGGA | VATLAATDLR | GKGYP----S | 191 |
| Humicola   | ADTLRQKVEL | AVREHPDYRV | VVTGHSLGGA | LATVAGADLR | GNGY-----D | 187 |
| Consensus  | .D.L...V.. | Q...HP.YKV | VVTGHSLGGA | .A.LAA.DLY | ..G....N   | 300 |
| .          |            |            |            |            |            |     |
| LIP_RHIMI  | LFLYTQGPQR | VGDPAFANYV | VST-GIPYRR | TVNERDIVPH | LPPAAFGLFH | 311 |
| LIP_RHIDL  | LSIFTVGGPR | VGNPTFAYYV | EST-GIPFQR | TVHKRDIVPH | VPPQSFGFLH | 341 |
| ABSIDIA    | IEIYTQGPQR | IGTPAFANYV | IGT-KIPYQR | LVHERDIVPH | LPPGAFGLFH | 288 |
| MDLA_PENCA | AKLYAYASPR | VGNAALAKYI | TAQ--GNNFR | FTHTNDPVPK | LPLLSMGYVH | 239 |
| Humicola   | IDVFSYGAPR | VGNRAFAEFL | TVQTGGTLYR | ITHTNDIVPR | LPPREFGYSH | 237 |
| Consensus  | ...YT.G.PR | VGNPAFA.YV | ..T-GIP..R | .VH.RDIVPH | LPP..FGFLH | 350 |
| .          |            |            |            |            |            |     |

Fig. 3 (a)  
SUBSTITUTE SHEET (RULE 26)

6/8

|            |            |            |            |            |            |             |     |
|------------|------------|------------|------------|------------|------------|-------------|-----|
| LIP_RHIMI  | AGEEYWITDN | SPETVQVC-T | SDLET----  | S          | DCSNSIVP-F | TSVLDHLSYF  | 355 |
| LIP_RHIDL  | PGVESWIKSG | TSN-VQIC-T | SEIET----  | K          | DCSNSIVP-F | TSILDHLSYF  | 384 |
| ABSIDIA    | AGEEFWIMKD | SSLRV--C-P | NGIET----  | D          | NCSNSIVP-F | TSVIDHLSYL  | 330 |
| MDLA_PENCA | VSPEYWITSP | NNATVSTSDI | KVIDGDVSFD | GNTGTGLPLL | TDFEAHIWYF | 289         |     |
| Humicola   | SSPEYWIKSG | TLVPVTRNDI | VKIEG---   | ID         | ATGGNNQPNI | PDIPAHLOWYF | 284 |
| Consensus  | .G.EYWI.S. | ....V..C-  | ..IET----  | D          | .CSNSIVP-F | TS..DHLSYF  | 400 |

|            |            |        |     |
|------------|------------|--------|-----|
| LIP_RHIMI  | GIN---TGLC | T----- | 363 |
| LIP_RHIDL  | DIN---EGSC | L----- | 392 |
| ABSIDIA    | DMN---TGLC | L----- | 338 |
| MDLA_PENCA | VQVDAGKGPG | LPFKRV | 305 |
| Humicola   | GLI----GTC | L----- | 291 |
| Consensus  | ..N---.G.C | L----- | 416 |

Fig. 3 (b)

SUBSTITUTE SHEET (RULE 26)

7/8

|           |            |             |            |            |            |     |
|-----------|------------|-------------|------------|------------|------------|-----|
| ABSIDIA   | M-----HSHF | VVLLLAVFIC  | MCSVSGVPL- | -----      | -----QIDP  | 28  |
| LIP_RHIMI | MV-LKQRANY | LGF-LIVFFT  | AFLVEAVPI- | -KRQSNSTV- | -----DSLPP | 40  |
| LIP_RHIDL | MVSFISISQG | VSLCLLVSSM  | MLGSSAVPVS | GKSGSSNTAV | SASDNAALPP | 50  |
| Consensus | MV-....S.. | V.L.L.VF..  | M..VSAVP.- | -K..S..T.- | -----LPP   | 50  |
| ABSIDIA   | -RDDKSYVPE | QYPLKVN---  | -----      | -----GPLP  | EGVSVIQGYC | 58  |
| LIP_RHIMI | LIPSRTSAPS | SSPSTTDPEA  | -P-AM----- | ---SRNGPLP | S--DVETKY- | 77  |
| LIP_RHIDL | LISSRCAPPS | NKGSKSDLQA  | EPYNMQKNT  | WYESHGGNLT | SIGKRDDNLV | 100 |
| Consensus | LI.SR...PS | ..PSK.D..A  | -P-.M----- | ---S..GPLP | S...V...Y. | 100 |
| ABSIDIA   | ENCTMYPEKN | SVSAFSSSST  | ----QD--YR | IASEAEIKAH | TFYTALSANA | 102 |
| LIP_RHIMI | -GMALNATSY | PDSVVQAMSI  | ----DGG-IR | AATSQEINEL | TYTTLSANS  | 121 |
| LIP_RHIDL | GGMTLDLPSD | APPISLSST   | NSASDGGKV  | AATTAQIQEF | TKYAGIAATA | 150 |
| Consensus | .GMTL...S. | ..S...SSST  | ----DGG-.R | AAT.AEI.E. | T.YT.LSANA | 150 |
| ABSIDIA   | YCRTVIPGGR | WSCPFCGV-A  | SNLQITKTF  | TLITDTNVLV | AVGEKEKTIY | 151 |
| LIP_RHIMI | YCRTVIPGAT | WDCIHCA-T   | EDLKIIKTWS | TLIYDTNAMV | ARGDSEKTIY | 170 |
| LIP_RHIDL | YCRSVVPGNK | WDCVQCQKW   | PDGKIITFT  | SLLSDTNGYV | LRSDKQKTIY | 200 |
| Consensus | YCRTVIPG.. | WDC.HC...-  | .DLKIIKTFS | TLI.DTN..V | ARGDKEKTIY | 200 |
| ABSIDIA   | VVFRGTSSIR | NAIADIVFVP  | VNYPPVNGAK | VHKGFLDSYN | EVQDKLVAEV | 201 |
| LIP_RHIMI | IVFRGSSSIR | NWIADLTFVP  | VSYPVSGTK  | VHKGFLDSYG | EVQNELVATV | 220 |
| LIP_RHIDL | LVFRGTNSFR | SAITDIVFNF  | SDYKPVKGAK | VHAGFLSSYE | QVVNDYFPVV | 250 |
| Consensus | .VFRGTSSIR | NAIADIVFVP  | V.YPPV.GAK | VHKGFLDSY. | EVQN.LVA.V | 250 |
| ABSIDIA   | KAQLDRHPGY | KIVVTGHS LG | GATAVLSALD | LYHHGH---- | ANIEIYTQGG | 247 |
| LIP_RHIMI | LDQFKQYPSY | KVAVTGHS LG | GATALLCALD | LYQREGLSS  | SNLFLYTQGG | 270 |
| LIP_RHIDL | QEQLTAHPTY | KVIVTGHS LG | GAQALLAGMD | LYQREPLSP  | KNLSIFTVGG | 300 |
| Consensus | ..QL..HP.Y | KV.VTGHS LG | GATALL.ALD | LYQRE..LS. | .NL.IYTQGG | 300 |
| ABSIDIA   | PRIGTPAFAN | YVIGTKIPYQ  | RLVHERDIVP | HLPPGAFGFL | HAGEEFWIMK | 297 |
| LIP_RHIMI | PRVGDPAFAN | YVSTGIPYR   | RTVNERDIVP | HLPPAAFGL  | HAGEEYWITD | 320 |
| LIP_RHIDL | PRVGNPTFAY | YVESTGIPFQ  | RTVHKRDIVP | HVPQSFGL   | HPGVESWIKS | 350 |
| Consensus | PRVG.PAFAN | YV.STGIPYQ  | RTVHERDIVP | HLPP.AFGFL | HAGEE.WI.. | 350 |
| ABSIDIA   | DSSLRV--CP | NGIETDNCSN  | SIVPFTSVID | HLSYLDMNTG | LCL 338    |     |
| LIP_RHIMI | NSPETVQVCT | SDLETSDCSN  | SIVPFTSVLD | HLSYFGINTG | LCT 363    |     |
| LIP_RHIDL | GTSN-VQICT | SEIETKDCSN  | SIVPFTSILD | HLSYFDINEG | SCL 392    |     |
| Consensus | .SS..VQ.CT | S.IET.DCSN  | SIVPFTSVLD | HLSYFDINTG | LCL 393    |     |

Fig. 3 (c)

SUBSTITUTE SHEET (RULE 26)

8/8

|            |            |             |            |            |             |     |
|------------|------------|-------------|------------|------------|-------------|-----|
| Humicola   | MRSSL--VLF | FVSAWT-ALA  | SPIR-REVSQ | DLFNQFNLF  | QYSAAAYCGK  | 46  |
| MDLA_PENCA | MRLSFFTALS | AVASLGYPALP | GKLQSRDVST | SELDQFEFWV | QYAAAASYEA  | 50  |
| Consensus  | MR.S....L. | .V.....AL.  | .....R.VS. | ....QF.... | QY.AA.Y...  | 50  |
|            | .. . . .   | . . . . .   | . . . . .  | . . . . .  | . . . . .   |     |
| Humicola   | NNDAPAGTNI | TCTGNACPEV  | EKADATFLYS | FEDSGVGDTV | GFLALDNTNK  | 96  |
| MDLA_PENCA | DYTAQVGDKL | SCSKGNCPEV  | EATGATVSVD | FSDSTITDTA | GYIAVDHTNS  | 100 |
| Consensus  | ...A..G... | .C....CPEV  | E...AT..Y. | F.DS...D.. | G..A.D.TN.  | 100 |
|            | .. . . .   | . . . . .   | . . . . .  | . . . . .  | . . . . .   |     |
| Humicola   | LIVLSFRGSR | SIENWIGNLN  | FDLKEINDIC | SGCRGHDGFT | SSWRSVADTL  | 146 |
| MDLA_PENCA | AVVLAFRGSY | SVRNWVADAT  | F-VHTNPGLC | DGCLAELGFW | SSWKLVRDDI  | 149 |
| Consensus  | ..VL.FRGS. | S..NW.....  | F.....C    | .GC....GF. | SSW..V.D..  | 150 |
|            | .. . . .   | . . . . .   | . . . . .  | . . . . .  | . . . . .   |     |
| Humicola   | RQKVEDAVRE | HPDYRVVFTG  | HSLGGALATV | AGADLRNGY  | -DIDVFSYGA  | 195 |
| MDLA_PENCA | IKELKEVVAQ | NPNYELVVVG  | HSLGAAVATL | AATDLRGKY  | PSAKLYAYAS  | 199 |
| Consensus  | .....V..   | .P.Y..V..G  | HSLG.A.AT. | A..DLRG.GY | .....Y..    | 200 |
|            | .. . . .   | . . . . .   | . . . . .  | . . . . .  | . . . . .   |     |
| Humicola   | PRVGNRAFAE | FLTVQTGGTL  | YRITHTNDIV | PRLPPREFGY | SHSSPEYWIK  | 245 |
| MDLA_PENCA | PRVGNAALAK | YITAQ--GNN  | FRFTHTNDPV | PKLPLLSMGY | VHVSPEYWIT  | 247 |
| Consensus  | PRVGN.A.A. | ..T.Q..G..  | .R.THTND.V | P.LP....GY | .H.SPEYWI.  | 250 |
|            | .. . . .   | . . . . .   | . . . . .  | . . . . .  | . . . . .   |     |
| Humicola   | SGTLVPVTRN | DIVKIEG---  | IDATGGNNQP | NIPDIPAHW  | YFGLI-----G | 288 |
| MDLA_PENCA | SPNNATVSTS | DIKVIDGDVS  | FDGNTGTGLP | LLTDFEAIW  | YFVQVDAGKG  | 297 |
| Consensus  | S.....V... | DI..I.G...  | .D...G...P | ...D..AH.W | YF.....G    | 300 |
|            | .. . . .   | . . . . .   | . . . . .  | . . . . .  | . . . . .   |     |
| Humicola   | TCL-----   |             |            |            |             | 291 |
| MDLA_PENCA | PGLPFKRV   |             |            |            |             | 305 |
| Consensus  | ..L.....   |             |            |            |             | 308 |
|            | .. . . .   |             |            |            |             |     |

Fig. 3 (d)

SUBSTITUTE SHEET (RULE 26)

# INTERNATIONAL SEARCH REPORT

1

International application No.

PCT/DK 98/00105

## A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C12N 15/10, C12Q 1/68

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C12N, C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|-----------|---|-----------------------|
| X         | WO 9522625 A1 (AFFYMAX TECHNOLOGIES N.V.),<br>24 August 1995 (24.08.95), page 9, line 6 - line 8;<br>page 78, line 16 - line 25, claim 12 | 1-2,5-6               |
| A         | -----<br>-----  | 3-4,7-8               |

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

2 July 1998

Date of mailing of the international search report

03-07-1998

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Patrick Andersson

Telephone No. +46 8 782 25 00

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International application No.

09/06/98

PCT/DK 98/00105

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|---|---------------------|----------------------------|---------------------|
| WO 9522625 A1                             | 24/08/95            | AU 2971495 A               | 04/09/95            |
|   |                     | CA 2182393 A               | 24/08/95            |
|   |                     | CN 1145641 A               | 19/03/97            |
|   |                     | EP 0752008 A               | 08/01/97            |
|   |                     | JP 10500561 T              | 20/01/98            |
|   |                     | US 5605793 A               | 25/02/97            |
| -----                                     |                     |                            |                     |

Form PCT/ISA/210 (patent family annex) (July 1992)